<DOC>
	<DOCNO>NCT02574091</DOCNO>
	<brief_summary>This phase I study evaluate safety , tolerability pharmacokinetics Icotinib Hydrochloride Cream healthy adult patient mild moderate psoriasis .</brief_summary>
	<brief_title>Icotinib Hydrochloride Cream Healthy Adults Psoriasis Patients</brief_title>
	<detailed_description>Icotinib Hydrochloride small-molecule epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor , approve treatment advance non-small-cell lung cancer ( NSCLC ) China oral form . As EGFR implicate pathogenesis psoriasis , icotinib hydrochloride develop cream treatment mild moderate psoriasis . This single-center , randomize , double-blind , placebo-controlled study icotinib hydrochloride cream topical administration . The study design two part healthy subject ( part 1 ) follow patient mild moderate psoriasis ( part 2 ) . 1 % 2 % icotinib hydrochloride cream initially apply healthy subject . Once study healthy adult show favorable safety tolerability , study patient mild moderate psoriasis follow . Approximately 28 subject enrol , include 12 healthy subject ( Part 1 ) 16 patient psoriasis ( Part 2 ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>For Part 1Healthy Participants 1850 year old ( inclusive ) , male female Male participant ≥ 50 kg , female participant ≥ 45 kg ; Body Mass Index ( BMI ) 19 30 kg/m2 ( inclusive ) In good health , history disease major organ BP , HR , ECG respiratory abnormality physical examination Adequate hepatic renal function , determine clinical laboratory assessment blood urine Negative serum pregnancy test Screening negative urine pregnancy test Day 1 female child bear potential Negative screen drug abuse , alcohol , hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) Human Immunodeficiency Virus ( HIV ) screening ; negative drug abuse , alcohol pre dose Day 1 Have sign write informed consent enter study For Part 2 Patients Psoriasis Clinical diagnosis psoriasis least six month multiple affect area ( exclude face , scalp , genitals groin ) involve 2 % 15 % total Body Surface Area ( BSA ) 1865 year old Male participant ≥ 50 kg , female participant ≥ 45 kg ; BMI 19 35 kg/m2 ( inclusive ) In good health , history disease major organ BP , HR , ECG respiratory abnormality physical examination Adequate hepatic renal function , determine clinical laboratory assessment blood urine Negative serum pregnancy test Screening negative urine pregnancy test Day 1 female child bear potential Negative screen drug abuse , alcohol , HBsAg , HCV HIV screening ; negative drug abuse , alcohol pre dose Day1 Women childbearing potential must agree use adequate contraception prior study entry , duration study participation , 90 day follow completion therapy Have sign write informed consent enter study For Part 1Healthy Participants Any clinically significant central nervous system , cardiac , pulmonary , renal , gastrointestinal , respiratory , metabolic condition ( history ) , pathological physiological condition might interfere trial result History postural hypotension Use topical agent ( include nonmedicated lotion sun screen , cosmetic , moisturize lotion ) administration site within week randomization History serious skin disease ( determine investigator ) ; presence skin ulceration test area time Screening visit Current smoker , history regular ( weekly ) use tobacco nicotinecontaining product within two month prior screen History excessive alcohol intake ( four standard drink daily , average ) use recreational drug within last three month For Part 2 Patients Psoriasis Any clinically significant central nervous system , cardiac , pulmonary , renal , gastrointestinal , respiratory , metabolic condition ( history ) , pathological physiological condition might interfere trial result History postural hypotension Use topical agent ( include nonmedicated lotion sun screen , cosmetic , moisturize lotion ) administration site within week randomization History serious skin disease ( determine investigator ) ; presence skin ulceration test area time Screening visit Excessive smoker ( ≥10 cigarette per day ) , history regular ( weekly ) use tobacco nicotinecontaining product within two month prior screen History excessive alcohol intake ( four standard drink daily , average ) use recreational drug within last three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EGFR inhibitor</keyword>
	<keyword>topical agent</keyword>
	<keyword>psoriasis</keyword>
	<keyword>phase 1</keyword>
</DOC>